(Total Views: 523)
Posted On: 09/10/2019 3:23:52 PM
Post# of 145873
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
I hear a lot of excitement from NP and this board but I do not see how NP's video answers the most important question of near term financing. "Revenue" in Q2 2020 ( he never mentioned the word significant) and a NON-BINDING agreement sounds like additional dilutive financing is likely to be required.
The only revenue I've seen mentioned until now was selling tiny quantities of non-clinical grade leronlimab.
Hope I'm wrong. GLTA.
The only revenue I've seen mentioned until now was selling tiny quantities of non-clinical grade leronlimab.
Hope I'm wrong. GLTA.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)